PHOENIX, Arizona — High-grade gliomas are cancerous tumors that spread quickly in the brain or spinal cord. In a new study led by Mayo Clinic, researchers found invasive brain tumor margins of high-grade glioma (HGG) contain biologically distinct genetic and molecular alterations that point to aggressive behavior and disease recurrence. The findings...
Latest News
For decades they have been looking for the few and the proud. In Chris Kaag, the Marines found such a man. A Marine is a Marine. There is no such thing as a former Marine, according to the 35th Commandant of the Marine Corps, Gen. James F. Amos. When your...
RADNOR, Pa. – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the...
RADNOR, Pa. – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Saraswathy (“Sara”) Nochur, Ph.D., to its Board of Directors. “Sara brings tremendous experience and success in managing global regulatory and drug development and...
RADNOR, Pa.- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the hiring of Steven E. Pfanstiel as Chief Financial Officer and Lisa Lejuwaan to the newly created position of Vice President of Sales. The appointments reflect...
RADNOR, Pa. – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Santiago Arroyo, M.D., Ph.D., to its Board of Directors. Dr. Arroyo brings more than 30 years of experience in academic neurology and pharmaceutical...
Cells that form cutaneous squamous cell carcinoma tumours prepare themselves to migrate to the lymph nodes to metastasise other organs, and they make changes so that they can survive this process. According to a study led by researchers from the Inflammatory and Neoplastic Dermatological Diseases Research Group at the Hospital del Mar Medical Research Institute, published in the journal Life Science Alliance, these cells stop consuming glucose so that they can survive by using LDL cholesterol molecules, the so-called bad cholesterol. This new marker may be a promising candidate for treatments involving lipid metabolism inhibitors targeting these cells to prevent metastasis.
HOUSTON – Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced completion of the six-patient safety lead-in portion of the Company’s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product...
London — MarketsandMarkets is pleased to announce the 4th Annual Orphan Drugs and Rare Diseases Conference, which is set to take place on the 9th-10th of October 2023 in London, UK. After the resounding success of the third annual conference, we are excited to bring together industry experts, researchers, and...
Calgary, Alberta – Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBraiN Inserm Lab in Tours, France. The study demonstrated that a single oral dose of MB-204 can restore...